These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34404444)

  • 21. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
    Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
    J Big Data; 2022; 9(1):92. PubMed ID: 35855914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-deletion to oligodendroglioma.
    Wong D; Lee TH; Lum A; Tao VL; Yip S
    Acta Neuropathol Commun; 2022 May; 10(1):70. PubMed ID: 35526077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Lower Grade Glioma Antigens Based on Ferroptosis Status for mRNA Vaccine Development.
    Zhao Z; Xing N; Guo H; Li J; Sun G
    Pharmgenomics Pers Med; 2024; 17():105-123. PubMed ID: 38623558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening TCGA database for prognostic genes in lower grade glioma microenvironment.
    Ni J; Liu S; Qi F; Li X; Yu S; Feng J; Zheng Y
    Ann Transl Med; 2020 Mar; 8(5):209. PubMed ID: 32309356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
    Zhao WJ; Ou GY; Lin WW
    Front Immunol; 2021; 12():682415. PubMed ID: 34054873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development.
    Wang ZL; Huang RY; Han B; Wu F; Sun ZY; Li GZ; Zhang W; Zhao Z; Liu X
    Chin Neurosurg J; 2022 Oct; 8(1):34. PubMed ID: 36307882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
    Li J; Zhang Y; Qu Z; Ding R; Yin X
    Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development.
    Fu J; Chen F; Lin Y; Gao J; Chen A; Yang J
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):4047-4061. PubMed ID: 36038676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
    Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
    Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Tumor Antigens and Immune Subtypes of High-grade Serous Ovarian Cancer for mRNA Vaccine Development.
    Wu Y; Li Z; Lin H; Wang H
    J Cancer; 2023; 14(14):2655-2669. PubMed ID: 37779866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma.
    Su X; Li H; Chen S; Qin C
    Technol Cancer Res Treat; 2021; 20():15330338211010143. PubMed ID: 33896271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma.
    Zhang S; Li S; Wei Y; Xiong Y; Liu Q; Hu Z; Zeng Z; Tang F; Ouyang Y
    Front Cell Dev Biol; 2022; 10():879278. PubMed ID: 35846349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
    Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
    Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stemness subtypes in lower-grade glioma with prognostic biomarkers, tumor microenvironment, and treatment response.
    Ye S; Yang B; Yang L; Wei W; Fu M; Yan Y; Wang B; Li X; Liang C; Zhao W
    Sci Rep; 2024 Jun; 14(1):14758. PubMed ID: 38926605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of tumor microenvironment-related genes in lower-grade gliomas by mining TCGA database.
    Liang H; Huang C
    Transl Cancer Res; 2020 Aug; 9(8):4583-4595. PubMed ID: 35117823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
    Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
    J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying Potential Tumor Antigens and Antigens-Related Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development.
    Liao W; Shi Z; Tang H; Wu T; Zhang C; He Y; Zou R; Wang L
    J Oncol; 2022; 2022():6851026. PubMed ID: 36072981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of γ-aminobutyric acidergic synapse-associated signature for lower-grade gliomas.
    Jiang H; Sun Z; Li F; Chen Q
    Front Immunol; 2022; 13():983569. PubMed ID: 36405708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.